Joshua M Hare

List of Publications by Year
in descending order

187	17,129	17405 63	14702 127
papers	citations	h-index	g-index

196	196	196	17013
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Results and insights from a phase I clinical trial of Lomecelâ€B for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 261-273.	0.4	17
2	Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. Cardiovascular Research, 2023, 118, 3586-3601.	1.8	9
3	Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovascular Research, 2022, 118, 2428-2436.	1.8	6
4	Systemic delivery of large-scale manufactured Whartonâ€™s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction. , 2022, 2, .		4
5	Stem cellsâ€™ potential to restore function in aging systems; are we there yet?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, , .	1.7	0
6	Comparative Effects of Bone Marrow-derived Versus Umbilical Cord Tissue Mesenchymal Stem Cells in an Experimental Model of Bronchopulmonary Dysplasia. Stem Cells Translational Medicine, 2022, 11, 189-199.	1.6	9
7	Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Journal of Urology, 2022, 207, 1295-1301.	0.2	16
8	Bilateral pneumonectomy and lung transplant for COVIDâ€“19-induced respiratory failure. JTCVS Techniques, 2022, , .	0.2	1
9	Leptin secreted from testicular microenvironment modulates hedgehog signaling to augment the endogenous function of Leydig cells. Cell Death and Disease, 2022, 13, 208.	2.7	7
10	Free-breathing gradient recalled echo-based CMR in a swine heart failure model. Scientific Reports, 2022, 12, 3698.	1.6	1
11	Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study. Cytotherapy, 2022, 24, 691-698.	0.3	1
12	Sâ€Nitrosoglutathione Reductase Deficiency Causes Aberrant Placental Sâ€Nitrosylation and Preeclampsia. Journal of the American Heart Association, 2022, 11, e024008.	1.6	7
13	Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD) Tj ETQq1 1 0.784314 rgBT /Overloc	0.6	6
14	Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method. Expert Opinion on Biological Therapy, 2022, 22, 449-463.	1.4	8
15	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine, 2022, 11, 688-703.	1.6	13
16	Meta-Analysis of Percutaneous Endomyocardial Cell Therapy in Patients with Ischemic Heart Failure by Combination of Individual Patient Data (IPD) of ACCRUE and Publication-Based Aggregate Data. Journal of Clinical Medicine, 2022, 11, 3205.	1.0	4
17	Col4a3-/- Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds. International Journal of Molecular Sciences, 2022, 23, 6674.	1.8	4
18	Mesenchymal Stem Cell-derived Extracellular Vesicles Prevent Experimental Bronchopulmonary Dysplasia Complicated By Pulmonary Hypertension. Stem Cells Translational Medicine, 2022, 11, 828-840.	1.6	13

#	Article	IF	Citations
19	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	6.1	589
20	The Presence of Cholesteryl Ester Transfer Protein (CETP) in Endothelial Cells Generates Vascular Oxidative Stress and Endothelial Dysfunction. Biomolecules, 2021, 11, 69.	1.8	11
21	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	12
22	Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. Vaccines, 2021, 9, 94.	2.1	67
23	S-nitrosoglutathione reductase (GSNOR) deficiency accelerates cardiomyocyte differentiation of induced pluripotent stem cells. , 2021, 1, .		0
24	Editorsâ€™ Preamble to The Journal of Cardiovascular Aging. , 2021, 1, .		0
25	Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. ESC Heart Failure, 2021, 8, 2306-2309.	1.4	13
26	Demographic representation in clinical trials for cell-based therapy. Contemporary Clinical Trials Communications, 2021, 21, 100702.	0.5	8
27	A Phase <scp>II</scp> study of autologous mesenchymal stromal cells and câ€kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the <scp>CCTRN CONCERTâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 661-674.	2.9	89
28	The Interdisciplinary Stem Cell Instituteâ€™s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases. Frontiers in Cell and Developmental Biology, 2021, 9, 675738.	1.8	1
29	Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease. Experimental Neurology, 2021, 341, 113706.	2.0	29
30	The National Heart, Lung, and Blood Instituteâ€funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy. Clinical and Translational Science, 2021, 14, 2099-2110.	1.5	1
31	Improvement of cardiac and systemic function in old mice by agonist of growth hormoneâ€releasing hormone. Journal of Cellular Physiology, 2021, 236, 8197-8207.	2.0	8
32	Can't Patch Everything: Personalized Medicine for Cell Therapy in Dilated Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021867.	1.6	1
33	COVID-19 Endothelial Dysfunction Can Cause Erectile Dysfunction: Histopathological, Immunohistochemical, and Ultrastructural Study of the Human Penis. World Journal of Men?s Health, 2021, 39, 466.	1.7	86
34	Kaposiâ€™s sarcoma herpesvirus activates the hypoxia response to usurp HIF2Î±-dependent translation initiation for replication and oncogenesis. Cell Reports, 2021, 37, 110144.	2.9	6
35	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy HeartÂFailure Patients. JACC: CardioOncology, 2020, 2, 581-595.	1.7	24
36	A novel cardiomyogenic role for Isl1 ⁺ neural crest cells in the inflow tract. Science Advances, 2020, 6, .	4.7	10

#	Article	IF	Citations
37	Rejuvenation of Senescent Endothelial Progenitor Cells by Extracellular Vesicles Derived From Mesenchymal Stromal Cells. JACC Basic To Translational Science, 2020, 5, 1127-1141.	1.9	19
38	Clinical evaluation of allogeneic mesenchymal stem cells for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046634.	0.4	2
39	Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Translational Medicine, 2020, 9, 1007-1022.	1.6	85
40	COVID19: A Systematic Approach to Early Identification and Healthcare Worker Protection. Frontiers in Public Health, 2020, 8, 205.	1.3	28
41	The Effect of Transendocardial Stem Cell Injection on Erectile Function in Men with Cardiomyopathy: Results From the TRIDENT, POSEIDON, and TAC-HFT Trials. Journal of Sexual Medicine, 2020, 17, 695-701.	0.3	10
42	The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy. Cardiovascular Research, 2020, 116, 2131-2141.	1.8	10
43	Clinical-based Cell Therapies for Heart Diseaseâ€"Current and Future State. Rambam Maimonides Medical Journal, 2020, 11, e0015.	0.4	17
44	Clinical and Neurophysiological Changes after Targeted Intrathecal Injections of Bone Marrow Stem Cells in a C3 Tetraplegic Subject. Journal of Neurotrauma, 2019, 36, 500-516.	1.7	17
45	Progenitor/Stem Cell Delivery by Suprarenal Aorta Route in Acute Kidney Injury. Cell Transplantation, 2019, 28, 1390-1403.	1.2	7
46	Actions and Potential Therapeutic Applications of Growth Hormoneâ€"Releasing Hormone Agonists. Endocrinology, 2019, 160, 1600-1612.	1.4	51
47	Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience. Aging Medicine (Milton (N S W)), 2019, 2, 142-146.	0.9	16
48	A metaâ€analysis of arrhythmia endpoints in randomized controlled trials of transendocardial stem cell injections for chronic ischemic heart disease. Journal of Cardiovascular Electrophysiology, 2019, 30, 2492-2500.	0.8	3
49	Mesenchymal Stem Cell Secretion of SDF-1Î± Modulates Endothelial Function in Dilated Cardiomyopathy. Frontiers in Physiology, 2019, 10, 1182.	1.3	20
50	Regenerative Medicine and the Biology of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1339-1340.	1.7	1
51	Attenuation of frailty in older adults with mesenchymal stem cells. Mechanisms of Ageing and Development, 2019, 181, 47-58.	2.2	16
52	Cell-Based Therapy Restores Olfactory Function in an Inducible Model ofÂHyposmia. Stem Cell Reports, 2019, 12, 1354-1365.	2.3	33
53	Age Induced Nitroso-Redox Imbalance Leads to Subclinical Hypogonadism in Male Mice. Frontiers in Endocrinology, 2019, 10, 190.	1.5	5
54	Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage: Case Report and Literature Review. World Neurosurgery, 2019, 128, 573-575.	0.7	13

#	Article	IF	Citations
55	Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 1-13.	1.2	68
56	Tumor Suppressors RB1 and CDKN2a Cooperatively Regulate Cell-Cycle Progression and Differentiation During Cardiomyocyte Development and Repair. Circulation Research, 2019, 124, 1184-1197.	2.0	32
57	Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy. EBioMedicine, 2019, 48, 377-385.	2.7	20
58	PDGFRA defines the mesenchymal stem cell Kaposiâ€™s sarcoma progenitors by enabling KSHV oncogenesis in an angiogenic environment. PLoS Pathogens, 2019, 15, e1008221.	2.1	23
59	Mesenchymal stem cell perspective: cell biology to clinical progress. Npj Regenerative Medicine, 2019, 4, 22.	2.5	1,113
60	Subcutaneous Leydig Stem Cell Autograft: A Promising Strategy to Increase Serum Testosterone. Stem Cells Translational Medicine, 2019, 8, 58-65.	1.6	27
61	Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology, 2019, 93, e1328-e1338.	1.5	33
62	Kidney-Derived c-Kit+ Cells Possess Regenerative Potential. Stem Cells Translational Medicine, 2018, 7, 317-324.	1.6	14
63	S-Nitrosoglutathione Reductase (GSNOR) Deficiency Results in Secondary Hypogonadism. Journal of Sexual Medicine, 2018, 15, 654-661.	0.3	9
64	Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility. Circulation Research, 2018, 122, 933-944.	2.0	129
65	Cigarette Smoke Initiates Oxidative Stress-Induced Cellular Phenotypic Modulation Leading to Cerebral Aneurysm Pathogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 610-621.	1.1	56
66	Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit ⁺) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.0	94
67	Preclinical Studies of Stem Cell Therapy for Heart Disease. Circulation Research, 2018, 122, 1006-1020.	2.0	104
68	Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7, 511-512.	1.6	0
69	Kidney-derived c-kit+ progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria. Scientific Reports, 2018, 8, 14723.	1.6	16
70	Mesenchymal Stem Cell Therapy for Aging Frailty. Frontiers in Nutrition, 2018, 5, 108.	1.6	38
71	Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine. Circulation Research, 2018, 123, 1030-1032.	2.0	3
72	Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11298-11303.	3.3	38

#	Article	IF	Citations
73	Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Molecular Therapy, 2018, 26, 1610-1623.	3.7	241
74	Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy. Journal of the American Heart Association, 2018, 7, .	1.6	29
75	Clinical Studies of Cell Therapy in Cardiovascular Medicine. Circulation Research, 2018, 123, 266-287.	2.0	129
76	Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. American Heart Journal, 2018, 201, 54-62.	1.2	17
77	Abstract TP91: Multiple Intra-arterial Dosing of the Mesenchymal Stem Cells Reduces Ischemic Brain Injury in a Rat Stroke Model. Stroke, 2018, 49, .	1.0	0
78	The quest for a successful cell-based therapeutic approach for heart failure. European Heart Journal, 2017, 38, 661-664.	1.0	7
79	What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction. Circulation Research, 2017, 120, 252-255.	2.0	23
80	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease. Circulation, 2017, 135, 1417-1428.	1.6	46
81	Effects of Transendocardial Stem Cell Injection on Ventricular Proarrhythmia in Patients with Ischemic Cardiomyopathy: Results from the POSEIDON and TAC-HFT Trials. Stem Cells Translational Medicine, 2017, 6, 1366-1372.	1.6	22
82	Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1505-1512.	1.7	71
83	Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER). Chest, 2017, 151, 971-981.	0.4	186
84	Next-Generation Stem Cell Therapy: Genetically Modified Mesenchymal Stem Cells for Cardiac Repair. Cardiovascular Drugs and Therapy, 2017, 31, 5-7.	1.3	7
85	Route of Delivery Modulates the Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction. Circulation Research, 2017, 120, 1139-1150.	2.0	155
86	Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12033-12038.	3.3	44
87	New insights into cellâ€based therapy for heart failure from the CHARTâ€1 study. European Journal of Heart Failure, 2017, 19, 1530-1533.	2.9	8
88	Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1513-1522.	1.7	107
89	Hypoxic Stress Decreases c-Myc Protein Stability in Cardiac Progenitor Cells Inducing Quiescence and Compromising Their Proliferative and Vasculogenic Potential. Scientific Reports, 2017, 7, 9702.	1.6	5
90	Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circulation Research, 2017, 121, 1279-1290.	2.0	152

#	Article	IF	Citations
91	Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. Journal of the American College of Cardiology, 2017, 70, 766-775.	1.2	82
92	A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration. Journal of the American College of Cardiology, 2017, 70, 2504-2515.	1.2	76
93	Experimental and Computational Insight Into Human Mesenchymal Stem Cell Paracrine Signaling and Heterocellular Coupling Effects on Cardiac Contractility and Arrhythmogenicity. Circulation Research, 2017, 121, 411-423.	2.0	56
94	Evidence for a retinal progenitor cell in the postnatal and adult mouse. Stem Cell Research, 2017, 23, 20-32.	0.3	9
95	Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. American Heart Journal, 2017, 192, 48-56.	1.2	38
96	GSNOR Deficiency EnhancesIn SituSkeletal Muscle Strength, Fatigue Resistance, and RyR1 S-Nitrosylation Without Impacting Mitochondrial Content and Activity. Antioxidants and Redox Signaling, 2017, 26, 165-181.	2.5	18
97	Randomized Comparison of Allogeneic Versus Autologous Mesenchymal StemÂCells for Nonischemic DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 526-537.	1.2	297
98	Stromal derived factor-1 mediates the lung regenerative effects of mesenchymal stem cells in a rodent model of bronchopulmonary dysplasia. Respiratory Research, 2017, 18, 137.	1.4	46
99	Physiological and hypoxic oxygen concentration differentially regulates human c-Kit⁺ cardiac stem cell proliferation and migration. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1509-H1519.	1.5	20
100	Mesenchymal Stem Cells in Cardiology. Methods in Molecular Biology, 2016, 1416, 55-87.	0.4	50
101	Stimulatory Effects of Mesenchymal Stem Cells on cKit + Cardiac Stem Cells Are Mediated by SDF1/CXCR4 and SCF/cKit Signaling Pathways. Circulation Research, 2016, 119, 921-930.	2.0	81
102	Pim1 Kinase Overexpression Enhances ckit+ Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine. Journal of the American College of Cardiology, 2016, 68, 2454-2464.	1.2	69
103	Olfactory basal stem cells: contribution of Polycomb group proteins to renewal in a novel c-Kit+ culture model and in vivo. Development (Cambridge), 2016, 143, 4394-4404.	1.2	25
104	Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue. Physiological Reviews, 2016, 96, 1127-1168.	13.1	251
105	Differentiation potential of individual olfactory câ€Kit+ progenitors determined via multicolor lineage tracing. Developmental Neurobiology, 2016, 76, 241-251.	1.5	21
106	Cell Therapy Augments Myocardial Perfusion and Improves Quality of Life in Patients With Refractory Angina. Circulation Research, 2016, 118, 911-915.	2.0	3
107	Murine Models Demonstrate Distinct Vasculogenic and Cardiomyogenic cKit ⁺ Lineages in the Heart. Circulation Research, 2016, 118, 382-387.	2.0	21
108	Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Translational Medicine, 2016, 5, 186-191.	1.6	109

#	Article	IF	Citations
109	Antagonism of stem cell factor/c-kit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling. Pediatric Research, 2016, 79, 637-646.	1.1	10
110	Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Oncotarget, 2016, 7, 11899-11912.	0.8	37
111	Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival?. Annals of Translational Medicine, 2016, 4, 243-243.	0.7	3
112	Adult c-Kit(+) progenitor cells are necessary for maintenance and regeneration of olfactory neurons. Journal of Comparative Neurology, 2015, 523, Spc1-Spc1.	0.9	0
113	S-nitrosylation and MSC-mediated body composition. Oncotarget, 2015, 6, 28517-28518.	0.8	1
114	Bone Marrow Mononuclear Cell Therapy and Granulocyte Colony-Stimulating Factor for Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 65, 2383-2387.	1.2	6
115	Growth Hormoneâ€“Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy. Journal of the American Heart Association, 2015, 4, .	1.6	26
116	Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 1990-1999.	1.2	133
117	Perspectives on the Evolution of Stem Cell Therapy for Heart Failure. EBioMedicine, 2015, 2, 1838-1839.	2.7	3
118	Effect of Aging on Human Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy Patients. Journal of the American College of Cardiology, 2015, 65, 125-132.	1.2	85
119	Mesenchymal Stem Cells as a Biological Drug for Heart Disease. Circulation Research, 2015, 117, 229-233.	2.0	56
120	Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4138-46.	3.3	63
121	Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells. EBioMedicine, 2015, 2, 467-475.	2.7	111
122	Allogeneic Cell Therapy. Circulation Research, 2015, 116, 12-15.	2.0	86
123	Xanthine Oxidase Inhibitors in Heart Failure. Circulation, 2015, 131, 1741-1744.	1.6	29
124	Regulation of oxygen delivery to the body via hypoxic vasodilation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6254-6255.	3.3	46
125	Cell Therapy. Circulation Research, 2015, 117, 659-661.	2.0	10
126	Sympathetic Reinnervation Is Required for Mammalian Cardiac Regeneration. Circulation Research, 2015, 117, 990-994.	2.0	97

#	Article	IF	Citations
127	S â€Nitrosoglutathione Reductase Deficiency Enhances the Proliferative Expansion of Adult Heart Progenitors and Myocytes Post Myocardial Infarction. Journal of the American Heart Association, 2015, 4, .	1.6	43
128	cKit ⁺ cardiac progenitors of neural crest origin. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13051-13056.	3.3	104
129	Dual Labeling Biotin Switch Assay to Reduce Bias Derived From Different Cysteine Subpopulations. Circulation Research, 2015, 117, 846-857.	2.0	31
130	Interaction Between Neuronal Nitric Oxide Synthase Signaling and Temperature Influences Sarcoplasmic Reticulum Calcium Leak. Circulation Research, 2015, 116, 46-55.	2.0	16
131	New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget, 2015, 6, 9728-9739.	0.8	23
132	Abstract 168: Intra-arterial Stem Cell Treatment Reduces Ischemic Brain Injury In Reproductively Senescent Female Rats. Stroke, 2015, 46, .	1.0	0
133	Efficacy and Dose-Dependent Safety of Intra-Arterial Delivery of Mesenchymal Stem Cells in a Rodent Stroke Model. PLoS ONE, 2014, 9, e93735.	1.1	83
134	Can Endothelial Progenitor Cells Treat Patients With Refractory Angina?. Circulation Research, 2014, 115, 904-907.	2.0	2
135	NADPH oxidase-2 inhibition restores contractility and intracellular calcium handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H710-H721.	1.5	32
136	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurology, 2014, 71, 141.	4.5	211
137	Emerging Applications of Stem Cell and Regenerative Medicine to Sports Injuries. Orthopaedic Journal of Sports Medicine, 2014, 2, 232596711351993.	0.8	10
138	Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17260-17265.	3.3	36
139	Long Term Ablation of Protein Kinase A (PKA)-mediated Cardiac Troponin I Phosphorylation Leads to Excitation-Contraction Uncoupling and Diastolic Dysfunction in a Knock-in Mouse Model of Hypertrophic Cardiomyopathy. Journal of Biological Chemistry, 2014, 289, 23097-23111.	1.6	29
140	Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides, 2014, 52, 104-112.	1.2	58
141	Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2014, 311, 62.	3.8	471
142	Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting. Circulation Research, 2014, 114, 1302-1310.	2.0	305
143	Association between serum uric acid and atrial fibrillation: A systematic review and meta-analysis. Heart Rhythm, 2014, 11, 1102-1108.	0.3	101
144	Mesenchymal Stem Cell Therapies in the Treatment of Musculoskeletal Diseases. PM and R, 2014, 6, 61-69.	0.9	55

#	Article	IF	Citations
145	Phase II Clinical Research Design in Cardiology. Circulation, 2013, 127, 1630-1635.	1.6	44
146	S -nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2834-2839.	3.3	89
147	Enhanced Effect of Combining Human Cardiac Stem Cells and Bone Marrow Mesenchymal Stem Cells to Reduce Infarct Size and to Restore Cardiac Function After Myocardial Infarction. Circulation, 2013, 127, 213-223.	1.6	375
148	C-Kit+Cells Isolated from Developing Kidneys Are a Novel Population of Stem Cells with Regenerative Potential. Stem Cells, 2013, 31, 1644-1656.	1.4	33
149	Stem cell factor improves lung recovery in rats following neonatal hyperoxia-induced lung injury. Pediatric Research, 2013, 74, 682-688.	1.1	17
150	Hydralazine and Organic Nitrates Restore Impaired Excitation-Contraction Coupling by Reducing Calcium Leak Associated with Nitroso-Redox Imbalance*. Journal of Biological Chemistry, 2013, 288, 6522-6533.	1.6	33
151	Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 559-563.	3.3	58
152	Dynamic denitrosylation via S -nitrosoglutathione reductase regulates cardiovascular function. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4314-4319.	3.3	122
153	Myocardial infarction and intramyocardial injection models in swine. Nature Protocols, 2012, 7, 1479-1496.	5.5	89
154	Comparison of Allogeneic vs Autologous Bone Marrowâ€"Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2012, 308, 2369.	3.8	1,017
155	Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy. Circulation Research, 2011, 108, 792-796.	2.0	286
156	Impaired S-Nitrosylation of the Ryanodine Receptor Caused by Xanthine Oxidase Activity Contributes to Calcium Leak in Heart Failure. Journal of Biological Chemistry, 2010, 285, 28938-28945.	1.6	126
157	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2604-2609.	3.3	95
158	Mesenchymal Stem Cell Therapy for Cardiac Repair. Methods in Molecular Biology, 2010, 660, 65-84.	0.4	88
159	Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation. Circulation Research, 2010, 107, 913-922.	2.0	659
160	Inhibition of the SDF-1/CXCR4 Axis Attenuates Neonatal Hypoxia-Induced Pulmonary Hypertension. Circulation Research, 2009, 104, 1293-1301.	2.0	83
161	Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14022-14027.	3.3	529
162	Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. European Heart Journal, 2009, 30, 2722-2732.	1.0	231

#	Article	IF	Citations
163	A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2009, 54, 2277-2286.	1.2	1,205
164	S-Nitrosylation of Cardiac Ion Channels. Journal of Cardiovascular Pharmacology, 2009, 54, 188-195.	0.8	119
165	Translational development of mesenchymal stem cell therapy for cardiovascular diseases. Texas Heart Institute Journal, 2009, 36, 145-7.	0.1	20
166	Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H2002-H2011.	1.5	152
167	Nitric Oxide and Cardiobiologyâ€Methods for Intact Hearts and Isolated Myocytes. Methods in Enzymology, 2008, 441, 369-392.	0.4	10
168	Cardiac regeneration and stem cell therapy. Current Opinion in Organ Transplantation, 2008, 13, 536-542.	0.8	58
169	Abstract 1753: Transcriptomic based Biomarkers Contain Diagnostic and Prognostic Information about Patients with new onset Heart Failure. Circulation, 2007, 116, .	1.6	0
170	Nitrosoâ€“Redox Interactions in the Cardiovascular System. Circulation, 2006, 114, 1531-1544.	1.6	147
171	NO/redox disequilibrium in the failing heart and cardiovascular system. Journal of Clinical Investigation, 2005, 115, 509-517.	3.9	307
172	Nitrosoâ€“Redox Balance in the Cardiovascular System. New England Journal of Medicine, 2004, 351, 2112-2114.	13.9	145
173	Nitric Oxide Regulation of Myocardial Contractility and Calcium Cycling. Circulation Research, 2003, 92, 1322-1329.	2.0	183
174	Nitric oxide and excitationâ€“contraction coupling. Journal of Molecular and Cellular Cardiology, 2003, 35, 719-729.	0.9	164
175	Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature, 2002, 416, 337-339.	13.7	724
176	Exhaled nitric oxide: a marker of pulmonary hemodynamics in heart failure. Journal of the American College of Cardiology, 2002, 40, 1114-1119.	1.2	26
177	Oxidative Stress and Apoptosis in Heart Failure Progression. Circulation Research, 2001, 89, 198-200.	2.0	105
178	Cardiac phosphodiesterase 5 (cGMPâ€specific) modulates Î²â€adrenergic signaling in vivo and is downâ€regulated in heart failure. FASEB Journal, 2001, 15, 1718-1726.	0.2	220
179	cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1982-H1988.	1.5	118
180	Left Ventricular or Biventricular Pacing Improves Cardiac Function at Diminished Energy Cost in Patients With Dilated Cardiomyopathy and Left Bundle-Branch Block. Circulation, 2000, 102, 3053-3059.	1.6	704

#	Article	IF	Citations
181	Contribution of Caveolin Protein Abundance to Augmented Nitric Oxide Signaling in Conscious Dogs With Pacing-Induced Heart Failure. Circulation Research, 2000, 86, 1085-1092.	2.0	111
182	Improved Mechanoenergetics and Cardiac Rest and Reserve Function of In Vivo Failing Heart by Calcium Sensitizer EMD-57033. Circulation, 2000, 101, 1040-1048.	1.6	72
183	Î²3-adrenoceptor deficiency blocks nitric oxideâ€“dependent inhibition of myocardial contractility. Journal of Clinical Investigation, 2000, 106, 697-703.	3.9	120
184	The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists. Nature Medicine, 1999, 5, 1241-1242.	15.2	12
185	Reduced left ventricular dimension and normalized atrial natriuretic hormone level after repair of aortic coarctation in an adult. Clinical Cardiology, 1999, 22, 233-235.	0.7	5
186	In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1416-H1422.	1.5	176
187	Ischemic cardiomyopathy: Endomyocardial biopsy and ventriculographic evaluation of patients with congestive failure, dilated cardiomyopathy and coronary artery disease. Journal of the American College of Cardiology, 1992, 20, 1318-1325.	1.2	63